{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:18:38Z","timestamp":1792441118558,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Unitaid"},{"DOI":"10.13039\/100005565","name":"Janssen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019120","name":"Otsuka","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The 2022 World Health Organization (WHO) guidelines on multidrug-resistant\/rifampicin-resistant tuberculosis (MDR\/RR-TB) recommend 6 months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen and 6 months or longer for Bdq and delamanid (Dlm) in the 18\u201320-month longer regimen. However, lack of evidence on extended treatment using Bdq or Dlm has limited their use to 6 months. We examine the frequency and incidence of QT prolongation based on duration of Bdq and\/or Dlm use in longer regimens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed a prospective cohort of MDR\/RR-TB patients from 16 countries who initiated treatment with Bdq and\/or Dlm containing regimens from 1 April 2015 to 30 September 2018. Data were systematically collected using a shared protocol. The outcome of interest was the first clinically relevant prolonged QT interval (grade 3 or above) or a serious adverse event (SAE) involving prolonged QT of any grade.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 2553 patients, 59% received &amp;gt;6 months of Bdq and\/or Dlm. Of these, 579 (20.9%) patients experienced a prolonged QT event, the majority (95.5%) being grade 1 or 2. Sixty-four (2.5%) patients experienced the outcome of interest with only 12 (0.5%) having \u22651 QT prolonging drugs permanently suspended. The incidence rate of the first prolonged QT event was highest in the first six months of treatment and lower in subsequent 6-month periods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We demonstrate that Bdq and\/or Dlm use beyond 6 months is safe in longer MDR\/RR-TB regimens with most clinically relevant QT prolongation events occurring in the first 6 months. Electrocardiogram (ECG) monitoring for early identification of QT prolongating events is possible in programmatic conditions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae601","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T21:00:53Z","timestamp":1733864453000},"page":"153-158","source":"Crossref","is-referenced-by-count":10,"title":["The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country Multidrug-Resistant\/Rifampicin-Resistant Tuberculosis Cohort"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3602-5950","authenticated-orcid":false,"given":"Uzma","family":"Khan","sequence":"first","affiliation":[{"name":"Interactive Research & Development (IRD) Global , Singapore ,","place":["Singapore"]},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4333-4695","authenticated-orcid":false,"given":"Michael","family":"Rich","sequence":"additional","affiliation":[{"name":"Division of Global Health Equity, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Partners In Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-5728","authenticated-orcid":false,"given":"Molly F","family":"Franke","sequence":"additional","affiliation":[{"name":"Partners In Health , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lachenal","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Unit, M\u00e9decins Sans Fronti\u00e8res , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Interactive Research & Development (IRD) , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amsalu","family":"Bekele","sequence":"additional","affiliation":[{"name":"Addis Ababa University College of Health Sciences , Addis Ababa ,","place":["Ethiopia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5371-9321","authenticated-orcid":false,"given":"Afshan K","family":"Isani","sequence":"additional","affiliation":[{"name":"Communicable Disease Control (CDC), Directorate General Health Services , Sindh ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-1479","authenticated-orcid":false,"given":"Catherine","family":"Hewison","sequence":"additional","affiliation":[{"name":"Medical Department, M\u00e9decins Sans\u202fFronti\u00e8res , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cut Yulia Indah","family":"Sari","sequence":"additional","affiliation":[{"name":"RS Islam Jakarta Cempaka Putih , Jakarta ,","place":["Indonesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilio L","family":"Tan","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans\u202fFronti\u00e8res , Minsk ,","place":["Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Varaine","sequence":"additional","affiliation":[{"name":"Medical Department, M\u00e9decins Sans\u202fFronti\u00e8res , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8869-4403","authenticated-orcid":false,"given":"Edwin Herrera","family":"Flores","sequence":"additional","affiliation":[{"name":"Arzobispo Loayza Hospital , Lima ,","place":["Peru"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9292-7787","authenticated-orcid":false,"given":"Fauziah Asnely","family":"Putri","sequence":"additional","affiliation":[{"name":"Interactive Research & Development (IRD) , Jakarta ,","place":["Indonesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil","family":"Faqirzai","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans\u202fFronti\u00e8res , Yerevan ,","place":["Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Beauchamp","sequence":"additional","affiliation":[{"name":"Zanmi\u202fLasante , Cange ,","place":["Haiti"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5937-6286","authenticated-orcid":false,"given":"Luan Nguyen Quang","family":"Vo","sequence":"additional","affiliation":[{"name":"Friends for International TB Relief , Hanoi ,","place":["Vietnam"]},{"name":"Department of Global Public Health, WHO Collaboration Centre on Tuberculosis and Social Medicine, Karolinska Institute , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Rafi","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Institute of Chest Diseases (ICD) Kotri , Sindh ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwonjune","family":"Seung","sequence":"additional","affiliation":[{"name":"Division of Global Health Equity, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Partners In Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Bastard","sequence":"additional","affiliation":[{"name":"Field Epidemiology Department, \u202fEpicentre , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Nkunkanyirazo","sequence":"additional","affiliation":[{"name":"Partners In Health , Lesotho, Maseru ,","place":["Lesotho"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Kiria","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans\u202fFronti\u00e8res , Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-2106","authenticated-orcid":false,"given":"Munira","family":"Khan","sequence":"additional","affiliation":[{"name":"Interactive\u202fResearch\u202f& Development (IRD) , Durban ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yerkebulan","family":"Algozhin","sequence":"additional","affiliation":[{"name":"Partners In Health , Almaty ,","place":["Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5303-8609","authenticated-orcid":false,"given":"Nara","family":"Melikyan","sequence":"additional","affiliation":[{"name":"Field Epidemiology Department, \u202fEpicentre , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0310-1626","authenticated-orcid":false,"given":"Nazis Arefin","family":"Saki","sequence":"additional","affiliation":[{"name":"National TB Programme , Dhaka ,","place":["Bangladesh"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stalz C","family":"Vilbrun","sequence":"additional","affiliation":[{"name":"GHESKIO Institute of Infectious Diseases and Reproductive Health, NTP , Port-au-Prince ,","place":["Haiti"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2340-6121","authenticated-orcid":false,"given":"Razia","family":"Fatima","sequence":"additional","affiliation":[{"name":"National TB Control Program, Common Management Unit (HIV, TB, Malaria) , Islamabad ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Yint","family":"Naing","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans\u202fFronti\u00e8res , Yangon ,","place":["Myanmar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirajul","family":"Islam","sequence":"additional","affiliation":[{"name":"Interactive\u202fResearch\u202f& Development (IRD) , Dhaka ,","place":["Bangladesh"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Mamsa","sequence":"additional","affiliation":[{"name":"Indus Hospital and Health Network (IHHN) , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3455-658X","authenticated-orcid":false,"given":"Carole D","family":"Mitnick","sequence":"additional","affiliation":[{"name":"Partners In Health , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0302-9063","authenticated-orcid":false,"given":"Helena","family":"Huerga","sequence":"additional","affiliation":[{"name":"Field Epidemiology Department, \u202fEpicentre , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0873-8355","authenticated-orcid":false,"given":"Palwasha Y","family":"Khan","sequence":"additional","affiliation":[{"name":"Interactive Research & Development (IRD) Global , Singapore ,","place":["Singapore"]},{"name":"Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"2025080104321583100_ciae601-B1","volume-title":"The use of bedaquiline in the treatment of multidrug-resistant tuberculosis","author":"World Health Organization","year":"2013"},{"key":"2025080104321583100_ciae601-B2","volume-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance","author":"World Health Organization","year":"2014"},{"key":"2025080104321583100_ciae601-B3","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment\u2014drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2022"},{"key":"2025080104321583100_ciae601-B4","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.5588\/ijtld.18.0423","article-title":"QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment","volume":"22","author":"Monedero-Recuero","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025080104321583100_ciae601-B5","doi-asserted-by":"crossref","first-page":"1701552","DOI":"10.1183\/13993003.01552-2017","article-title":"Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis","volume":"50","author":"Furin","year":"2017","journal-title":"The European respiratory journal"},{"key":"2025080104321583100_ciae601-B6","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"2025080104321583100_ciae601-B7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.clpt.2003.11.376","article-title":"Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors","volume":"75","author":"Amankwa","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"2025080104321583100_ciae601-B8","first-page":"63","article-title":"Clofazimine induced cardiotoxicity\u2013a case report","volume":"66","author":"Choudhri","year":"1995","journal-title":"Lepr Rev"},{"key":"2025080104321583100_ciae601-B9","doi-asserted-by":"crossref","first-page":"766","DOI":"10.5588\/ijtld.17.0840","article-title":"Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia","volume":"22","author":"Hewison","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025080104321583100_ciae601-B10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cid\/ciad589","article-title":"Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without human immunodeficiency virus: the impact of assumptions about death and missing follow-up","volume":"78","author":"Sauer","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025080104321583100_ciae601-B11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12879-019-4378-4","article-title":"The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens","volume":"19","author":"Khan","year":"2019","journal-title":"BMC infectious diseases"},{"key":"2025080104321583100_ciae601-B12","author":"endTB"},{"key":"2025080104321583100_ciae601-B13","author":"endTB"},{"key":"2025080104321583100_ciae601-B14","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.5588\/ijtld.20.0115","article-title":"Setting up pharmacovigilance based on available endTB project data for bedaquiline","volume":"24","author":"Lachenal","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025080104321583100_ciae601-B15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/ciac019","article-title":"Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort","volume":"75:","author":"Hewison","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025080104321583100_ciae601-B16","author":"endTB"},{"key":"2025080104321583100_ciae601-B17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/cid\/ciu786","article-title":"Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort","volume":"60","author":"Guglielmetti","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025080104321583100_ciae601-B18","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2021.1646","article-title":"Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: a nationwide study from Belarus, 2015\u201319","volume":"91","author":"Solodovnikova","year":"2021","journal-title":"Monaldi Arch Chest Dis"},{"key":"2025080104321583100_ciae601-B19","doi-asserted-by":"crossref","first-page":"ofab413","DOI":"10.1093\/ofid\/ofab413","article-title":"QT interval prolongation in people treated with bedaquiline for drug-resistant tuberculosis under programmatic conditions: a retrospective cohort study","volume":"8","author":"Isralls","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025080104321583100_ciae601-B20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40249-021-00819-2","article-title":"Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety","volume":"10","author":"Gao","year":"2021","journal-title":"Infect Dis Poverty"},{"key":"2025080104321583100_ciae601-B21","doi-asserted-by":"crossref","first-page":"1601799","DOI":"10.1183\/13993003.01799-2016","article-title":"Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis","volume":"49","author":"Guglielmetti","year":"2017","journal-title":"Eur Respir J"},{"key":"2025080104321583100_ciae601-B22","doi-asserted-by":"crossref","first-page":"00685-2021","DOI":"10.1183\/23120541.00685-2021","article-title":"Safety of prolonged treatment with bedaquiline in programmatic conditions","volume":"8","author":"Zhurkin","year":"2022","journal-title":"ERJ Open Res"},{"key":"2025080104321583100_ciae601-B23","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1183\/09031936.00132114","article-title":"Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation","volume":"44","author":"Migliori","year":"2014","journal-title":"Eur Respir J"},{"key":"2025080104321583100_ciae601-B24","doi-asserted-by":"crossref","first-page":"2002544","DOI":"10.1183\/13993003.02544-2020","article-title":"Emergence of bedaquiline-resistance in a high-burden country of tuberculosis","volume":"57","author":"Chesov","year":"2021","journal-title":"Eur Respir J"},{"key":"2025080104321583100_ciae601-B25","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.5588\/ijtld.20.0141","article-title":"Introducing new and repurposed TB drugs: the endTB experience","volume":"24","author":"Seung","year":"2020","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae601\/61018499\/ciae601.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/1\/153\/61018499\/ciae601.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/1\/153\/61018499\/ciae601.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T08:32:56Z","timestamp":1754037176000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/1\/153\/7920036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,10]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae601","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,15]]},"published":{"date-parts":[[2024,12,10]]}}}